Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$23.34 USD

23.34
2,847,490

-0.15 (-0.64%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $23.33 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now

by Zacks Equity Research

Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.

Here's Why You Should Retain McKesson (MCK) Stock for Now

by Zacks Equity Research

McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Here's Why You Should Hold on to OPKO Health (OPK) Stock Now

by Zacks Equity Research

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

XRAY vs. ALGN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Here's Why You Should Hold on to Masimo (MASI) Stock Now

by Zacks Equity Research

Masimo (MASI) raises 2019 revenue and EPS guidance.

Here's Why You Should Retain PRA Health (PRAH) Stock Now

by Zacks Equity Research

PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, escalating direct costs remain a woe.

Cooper Companies' CVI Unit Gets FDA Nod, To Boost Eye Health

by Zacks Equity Research

Cooper Companies' (COO) CVI Unit has receives FDA approval for its MiSight 1 day contact lens, which complements its commitment to eye health innovation.

Here's Why You Should Hold on to Becton, Dickinson Stock Now

by Zacks Equity Research

Becton, Dickinson (BDX) expects tariffs to impact its bottom line in first-quarter fiscal 2020.

Here's Why You Should Hold on to PerkinElmer Stock for Now

by Zacks Equity Research

PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.

Here's Why You Should Hold Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.

NextGen's Medfusion Buyout to Improve Patient Experience

by Zacks Equity Research

NextGen (NXGN) showcases new capabilities and services for its flagship NextGen Enterprise platform.

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Ups '19 View

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) gains from solid segmental contributions in Q3.

Dentsply International (XRAY) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 14.00% and 1.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products' Nov 7 Earnings Roster: ABC, CAH & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

XRAY or WST: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. WST: Which Stock Is the Better Value Option?

Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?

by Zacks Equity Research

CVS Health's (CVS) Caremark legacy business is expected to have delivered a solid third quarter, backed by the company's robust execution of its formulary and cost-containment tools.

What's in Store for DENTSPLY SIRONA (XRAY) in Q3 Earnings?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q3 earnings to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

Can All-Line Growth Boost CVS Health's (CVS) Q3 Earnings?

by Zacks Equity Research

The newly-incorporated Health Care Benefits business already registers top-line contributions for CVS Health (CVS).

Dentsply International (XRAY) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Dentsply (XRAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Genetic Testing Drive Invitae's (NVTA) Q3 Earnings?

by Zacks Equity Research

Several bio-pharma partnerships and acquisitions are likely to have contributed to Invitae's (NVTA) top line in Q3.

Can Dental Growth Drive Henry Schein's (HSIC) Q3 Earnings?

by Zacks Equity Research

The robust performance of the Primescan system in Europe and the United States is expected to have contributed to Henry Schein's (HSIC) top line during Q3.

Can BD Medical Drive Becton, Dickinson's (BDX) Q4 Earnings?

by Zacks Equity Research

Headwinds in the DCB business and unfavorable foreign exchange rates might have partially impacted Becton, Dickinson's (BDX) fiscal Q4 performance.

Why Dentsply (XRAY) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.